Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M99,974Revenue $M15,879Net Margin (%)12.6Z-Score5.5
Enterprise Value $M100,502EPS $1.2Operating Margin %16.3F-Score6
P/E(ttm))50.9Cash Flow Per Share $2.8Pre-tax Margin (%)15.0Higher ROA y-yN
Price/Book6.810-y EBITDA Growth Rate %-1.4Quick Ratio1.5Cash flow > EarningsY
Price/Sales6.45-y EBITDA Growth Rate %-14.3Current Ratio1.7Lower Leverage y-yY
Price/Cash Flow11.7y-y EBITDA Growth Rate %-21.1ROA % (ttm)5.8Higher Current Ratio y-yY
Dividend Yield %2.4Insider Buy (3m)0ROE % (ttm)13.2Less Shares Outstanding y-yN
Payout Ratio %121Shares Outstanding M1,659ROI % (ttm)5.7Gross Margin Increase y-yY

Gurus Latest Trades with BMY

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BMYRuane Cunniff 2014-12-31 Buy $48.92 - $61.3
($56.53)
$ 60.928%New holding, 3670 sh.3,670
BMYKen Fisher 2014-12-31 Reduce$48.92 - $61.3
($56.42)
$ 60.928%Reduce -39.96%30,739
BMYRay Dalio 2014-12-31 Sold Out $48.92 - $61.3
($56.42)
$ 60.928%Sold Out0
BMYVanguard Health Care Fund 2014-09-30 Add0.3%$47.86 - $51.96
($49.97)
$ 60.9222%Add 6.31%38,480,761
BMYRay Dalio 2014-09-30 Buy $47.86 - $51.96
($49.97)
$ 60.9222%New holding, 10228 sh.10,228
BMYJoel Greenblatt 2014-09-30 Sold Out -0.05%$47.86 - $51.96
($49.97)
$ 60.9222%Sold Out0
BMYVanguard Health Care Fund 2014-06-30 Add0.86%$46.59 - $52.19
($49.29)
$ 60.9224%Add 22.96%36,197,961
BMYJoel Greenblatt 2014-06-30 Buy 0.05%$46.59 - $52.19
($49.29)
$ 60.9224%New holding, 89363 sh.89,363
BMYRay Dalio 2014-06-30 Sold Out $46.59 - $52.19
($49.29)
$ 60.9224%Sold Out0
BMYKen Fisher 2014-06-30 Add$46.59 - $52.19
($49.29)
$ 60.9224%Add 216.1%49,732
BMYRonald Muhlenkamp 2014-03-31 Buy 1.9%$48.54 - $56.61
($53.23)
$ 60.9214%New holding, 212015 sh.212,015
BMYVanguard Health Care Fund 2014-03-31 Add0.73%$48.54 - $56.61
($53.21)
$ 60.9214%Add 20.35%29,437,761
BMYRay Dalio 2014-03-31 Buy $48.54 - $56.61
($53.23)
$ 60.9214%New holding, 4428 sh.4,428
BMYGeorge Soros 2014-03-31 Sold Out -0.05%$48.54 - $56.61
($53.23)
$ 60.9214%Sold Out0
BMYJoel Greenblatt 2014-03-31 Sold Out -0.02%$48.54 - $56.61
($53.23)
$ 60.9214%Sold Out0
BMYJoel Greenblatt 2013-12-31 Buy 0.02%$46.41 - $53.84
($50.96)
$ 60.9220%New holding, 11679 sh.11,679
BMYVanguard Health Care Fund 2013-09-30 Add0.64%$41.32 - $47.53
($43.84)
$ 60.9239%Add 20.26%24,459,861
BMYIrving Kahn 2013-09-30 Reduce-0.19%$41.32 - $47.53
($43.84)
$ 60.9239%Reduce -48.95%28,300
BMYJean-Marie Eveillard 2013-09-30 Reduce-0.01%$41.32 - $47.53
($43.84)
$ 60.9239%Reduce -75.17%16,520
BMYVanguard Health Care Fund 2013-06-30 Add0.39%$39.68 - $47.68
($43.41)
$ 60.9240%Add 13.32%20,338,461
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BMY is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
BMY Ruane Cunniff 2014-12-313,67000New Buy
BMY Irving Kahn 2014-12-3128,40000.29+2.71%
BMY Vanguard Health Care Fund 2014-12-3139,056,3612.355.4+1.5%
BMY Mario Gabelli 2014-12-31709,7150.040.22+1.35%
BMY Dodge & Cox 2014-12-3191,0280.010.01+0.66%
BMY Jean-Marie Eveillard 2014-12-3114,49200
BMY Brian Rogers 2014-12-316,264,8000.381.3
BMY Ronald Muhlenkamp 2014-12-31212,2900.012.5-0.09%
BMY Ken Fisher 2014-12-3130,73900-39.96%
BMY Ray Dalio 2014-12-31000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


BMY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
LEUNG SANDRAGeneral Counsel & Secretary 2015-02-17Sell11,746$60.390.88view
Moed Samuel JSVP, Strat Plan & Analysis 2015-02-12Sell3,880$59.262.8view
Moed Samuel JSVP, Strat Plan & Analysis 2015-02-06Sell21,478$60.151.28view
CORNELIUS JAMES MDirector 2015-01-30Sell50,000$60.60.53view
ANDREOTTI LAMBERTOCEO 2015-01-29Sell90,246$61.14-0.36view
CAMPBELL LEWIS BDirector 2015-01-29Sell2,500$60.890.05view
Schmukler Louis SPres., Global Mfg. & Supply 2015-01-29Sell5,250$60.730.31view
ANDREOTTI LAMBERTOCEO 2014-12-05Sell75,000$60.311.01view
ANDREOTTI LAMBERTOCEO 2014-11-05Sell75,000$57.795.42view
ANDREOTTI LAMBERTOCEO 2014-10-24Sell50,000$5314.94view

Press Releases about BMY :

    Quarterly/Annual Reports about BMY:

    News about BMY:

    Articles On GuruFocus.com
    Bayer Goes Into Disinvestment Mode Due To Falling Profit Numbers Feb 27 2015 
    Abner Herrman's Top Three Holdings Feb 26 2015 
    Biocept (BIOC) Soars on Liquid Biopsy Appreciation, Rigel Pharmaceuticals (RIGL) Mega-deal with Bris Feb 23 2015 
    Pharmaceuticals Sector To See High Voltage Action in 2015 Jan 23 2015 
    Feeling Good With This Med Company Jan 20 2015 
    mom Dec 27 2014 
    I think Zimmer Will Outperform S&P 500 Performance Dec 04 2014 
    A Buy Recommendation From Absolute Valuation Model to Bristol-Myers Squibb Nov 24 2014 
    Blackhill Bets Almost Half of Portfolio on Williams-Sonoma Nov 10 2014 
    A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio Nov 09 2014 

    More From Our Partners
    Bristol-Myers to Buy Flexus, Team Up with Rigel - Analyst Blog Feb 24 2015 - ZACKS

    More From Other Websites
    [$$] Biotech Sector Addicted to M&A Drug Feb 27 2015
    Final Glance: Pharmaceuticals companies Feb 27 2015
    U.S. Food and Drug Administration Accepts Biologics Licensing Application for Opdivo (nivolumab) for... Feb 27 2015
    1:34 pm Bristol-Myers announces that the FDA has accepted for filing and review the BLA for Opdivo... Feb 27 2015
    U.S. Food and Drug Administration Accepts Biologics Licensing Application for Opdivo (nivolumab) for... Feb 27 2015
    Midday Glance: Pharmaceuticals companies Feb 27 2015
    Early Glance: Pharmaceuticals companies Feb 27 2015
    5 Top-Heavy Stocks to Sell: Oracle, Michael Kors and More Feb 27 2015
    Bristol-Myers: Drug combo cured hepatitis C in 97% with HIV Feb 26 2015
    Study of Next-Generation Investigational HIV-1 Maturation Inhibitor Shows Positive Results in... Feb 26 2015
    ALLY Trial Demonstrates 97% Hepatitis C Cure Rates Among Patients Coinfected with HIV After... Feb 26 2015
    Bristol hep C drug helps cure 97 pct of HIV coinfected patients-study Feb 26 2015
    Rigel Pharma CEO pulls back the curtain on drug deal with Bristol-Myers Feb 26 2015
    Exchange-traded funds that hold big pharma Feb 26 2015
    Study of Next-Generation Investigational HIV-1 Maturation Inhibitor Shows Positive Results in... Feb 26 2015
    How to arrive at valuations for big pharma Feb 25 2015
    Bristol-Myers Squibb Launches Phase III Trial Of HIV Drug Feb 25 2015
    Eight Undervalued Key Antibiotics Players Feb 25 2015
    Bristol-Myers Squibb Foundation Awards GRU Cancer Center Three-Year, $1.74M Grant to Address Lung... Feb 25 2015
    48-Week Analysis of Investigational HIV-1 Attachment Inhibitor Paves Way for Phase III Trial... Feb 25 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK